Abstract
Highly active retroviral therapy (HAART) has been in widespread use in the United States since 1996. We sought to determine how the use of HAART influenced survival among patients with acquired immunodeficiency syndrome (AIDS) and primary central nervous system (CNS) non-Hodgkins lymphoma (NHL). We used the populationbased San Diego and Orange County cancer registry to identify 94 patients with both AIDS and CNS NHL diagnosed 1994-1999, of whom 31 were diagnosed 1996-1999. We performed Kaplan-Meier analyses to compare survival between patients who received HAART at NHL diagnosis or thereafter versus untreated patients and Cox proportional hazard models for adjusted survival. Among the patients diagnosed with NHL in 1996-1999, seven (23%) were taking HAART at the time of NHL diagnosis. Median survival was eight months for those who received HAART at the time of lymphoma diagnosis or after, versus one month for untreated patients. HAART, radiation therapy, and better performance status were associated with improved survival. We conclude that HAART prolongs survival in AIDS-related CNS NHL.
Keywords: Lymphoma, AIDS-related, antiretroviral therapy, highly active, survival, central nervous system
Current HIV Research
Title: Highly Active Antiretroviral Therapy is Associated with Improved Survival among Patients with AIDS-Related Primary Central Nervous System Non-Hodgkins Lymphoma
Volume: 4 Issue: 3
Author(s): Catherine Diamond, Thomas H. Taylor, Theresa Im, Mohammed Miradi, Mark Wallace and Hoda Anton-Culver
Affiliation:
Keywords: Lymphoma, AIDS-related, antiretroviral therapy, highly active, survival, central nervous system
Abstract: Highly active retroviral therapy (HAART) has been in widespread use in the United States since 1996. We sought to determine how the use of HAART influenced survival among patients with acquired immunodeficiency syndrome (AIDS) and primary central nervous system (CNS) non-Hodgkins lymphoma (NHL). We used the populationbased San Diego and Orange County cancer registry to identify 94 patients with both AIDS and CNS NHL diagnosed 1994-1999, of whom 31 were diagnosed 1996-1999. We performed Kaplan-Meier analyses to compare survival between patients who received HAART at NHL diagnosis or thereafter versus untreated patients and Cox proportional hazard models for adjusted survival. Among the patients diagnosed with NHL in 1996-1999, seven (23%) were taking HAART at the time of NHL diagnosis. Median survival was eight months for those who received HAART at the time of lymphoma diagnosis or after, versus one month for untreated patients. HAART, radiation therapy, and better performance status were associated with improved survival. We conclude that HAART prolongs survival in AIDS-related CNS NHL.
Export Options
About this article
Cite this article as:
Diamond Catherine, Taylor H. Thomas, Im Theresa, Miradi Mohammed, Wallace Mark and Anton-Culver Hoda, Highly Active Antiretroviral Therapy is Associated with Improved Survival among Patients with AIDS-Related Primary Central Nervous System Non-Hodgkins Lymphoma, Current HIV Research 2006; 4 (3) . https://dx.doi.org/10.2174/157016206777709429
DOI https://dx.doi.org/10.2174/157016206777709429 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design The Potential Biomedical Application of Cyclopeptides from Marine Natural Products
Current Organic Chemistry CD4+ T Cell Responses in the Immune Control Against Latent Infection by Epstein-Barr Virus
Current Molecular Medicine Preface
Current Pharmaceutical Design Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
Current Cancer Therapy Reviews Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry Nontoxic-dose of Deguelin Induce NPMc+ AML Cell Differentiation by Selectively Targeting Mt NPM1/SIRT1 Instead of HDAC1/3
Current Cancer Drug Targets Inflammation and Immunology of the Vitreoretinal Compartment
Inflammation & Allergy - Drug Targets (Discontinued) Implications of microRNAs in the Pathogenesis of Atherosclerosis and Prospects for Therapy
Current Drug Targets Recent Patents Concerning Diagnostic and Therapeutic Applications of Aberrantly Methylated Sequences in Pancreatic Cancer
Recent Patents on DNA & Gene Sequences Metals and Metal Derivatives in Medicine
Mini-Reviews in Medicinal Chemistry Heptahelical Receptors for Lysolipids in Lymphocytes as Targets for Therapeutic Intervention
Drug Design Reviews - Online (Discontinued) Using Insights into Pim1 Structure to Design New Anticancer Drugs
Current Pharmaceutical Design Extracellular Vesicles Isolated from Mesenchymal Stromal Cells Primed with Hypoxia: Novel Strategy in Regenerative Medicine
Current Stem Cell Research & Therapy The Genetic Basis of New Treatment Modalities in Melanoma
Current Drug Targets Cancer Stem Cells: Current Status and Therapeutic Implications in Cancer Therapy-A New Paradigm
Current Stem Cell Research & Therapy MicroRNAs and the Warburg Effect: New Players in an Old Arena
Current Gene Therapy Role of CHK2 Inhibitors in the Cellular Responses to Ionizing Radiation
Mini-Reviews in Medicinal Chemistry The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design